SCHEMBL4187079

SCHEMBL4187079

O=C(Cc1ccc(C(F)(F)F)cc1)c1c(O)c2cccnc2n(-c2cccc(OC(F)(F)F)c2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.41
PDE4D Q08499 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
PPARG P37231 1/20 0.40
DGAT2 Q96PD7 1/20 0.38
IDO1 P14902 1/20 0.37
BCL2L1 Q07817 1/20 0.37
TP53 P04637 2/20 0.37
POLB P06746 1/20 0.37
TOP2A P11388 1/20 0.37
P2RY1 P47900 1/20 0.37
CXCR3 P49682 3/20 0.37
CYP3A4 P08684 2/20 0.37
EP300 Q09472 1/20 0.37
CREBBP Q92793 1/20 0.37
KAT2A Q92830 1/20 0.37
KAT2B Q92831 1/20 0.37
MAPT P10636 1/20 0.36
FEN1 P39748 1/20 0.36
ROCK2 O75116 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4194557 0.94 BCL2L1 (0.43) PDE4BPDE4DIDO1BCL2L1TOP2A
SCHEMBL4189465 0.92 BCL2L1 (0.42) PDE4BPDE4DPPARGIDO1BCL2L1
SCHEMBL4187633 0.92 PPARG (0.41) PDE4BPDE4DPPARGIDO1TP53
SCHEMBL4188348 0.92 CNR2 (0.43) PDE4BPDE4DIDO1BCL2L1TP53
SCHEMBL4187682 0.92 PDE4B (0.43) PDE4BPDE4DPPARGIDO1TOP2A
SCHEMBL4190734 0.92 PPARG (0.41) PDE4BPDE4DPPARGIDO1TP53
SCHEMBL4185730 0.91 PDE4B (0.43) PDE4BPDE4DIDO1TOP2AFEN1
SCHEMBL4183644 0.90 TP53 (0.43) PDE4BPDE4DPTGDR2PPARGTP53
SCHEMBL4180891 0.87 CXCR3 (0.44) PDE4BPDE4DBCL2L1CXCR3CYP3A4
SCHEMBL4187823 0.86 PDE4B (0.40) PDE4BPDE4DIDO1TOP2ACXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1925617-B1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA PHARM CO LTD (JP) 2012-11-14 EP disclosed
US-8193356-B2 Heterocycle compound, and production process and application thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-05 US disclosed
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-21 US disclosed
EP-1925617-A1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA Pharmaceutical Co., Ltd. (JP) 2008-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof PDE3B, PDE4B, PDE7A PDE4B 2/4885PDE4D 7/4885PTGDR2 1522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.